A newly formed fund called MS1 has acquired a portfolio of interests in six clinical- and pre-clinical-stage companies from Index Venture Life VI – a life sciences fund advised by Medicxi.
PayPoint will use the proceeds to focus on core UK markets
Round for the biotechnology company extends the CHF 2.5m August 2019 round led by Redalpine
UnternehmerTUM Fonds III has a target of €150m and will focus on series-A and early-stage rounds
Deal is HTGF's 11th exit during the coronavirus pandemic, and comes seven years after the VC first invested in the company